BioLineRx Ltd. (BLRX.TA)
Tel Aviv · ILA · Healthcare · Biotechnology
ILA 1.00 (-9.09%) as of
Key statistics
- Market cap
- 29.87M
- EPS (TTM)
- 0.0000
- Dividend yield
- 0.00%
- 52-week range
- 1.0000 – 2.2000
- Beta
- 0.70
- Revenue (TTM)
- 1.39M
- Profit margin
- 0.00%
- Volume
- 11.02M
About BioLineRx Ltd.
BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Hevel Modi'in, Israel
- Employees
- 20
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.